# Day Zero Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/day-zero-diagnostics

- Industry: Medical Devices & Equipment
- Headquarters: Boston, US
- Website: www.dayzerodiagnostics.com
- Total disclosed funding: $33M
- Latest round: Series A (Feb 9, 2022)
- Investors on record: 6

## About

Based in the US, Day Zero Diagnostics, Inc. is a biotechnology company specializing in rapid diagnostic solutions for infectious diseases through whole genome sequencing, enabling immediate identification and antimicrobial susceptibility testing directly from blood samples.Founded in 2016 in Boston, US, Day Zero Diagnostics, Inc. focuses on innovating diagnostics for infectious diseases. The company was co-founded by Douglas Kwon, Jong Lee, Melis Anahtar, and Miriam Huntley. As of September 2023, Day Zero Diagnostics raised USD 16.00 mn in its latest funding round, accumulating a total of USD 16.00 mn through 6 deals.Day Zero Diagnostics Inc. (DZD) specializes in rapid diagnostics for infectious diseases, utilizing whole genome sequencing to deliver same-day identification (ID) and antimicrobial susceptibility testing (AST) directly from blood samples, circumventing traditional culture-based methods. Their flagship offering, the rapid antimicrobial susceptibility testing, empowers healthcare professionals to make informed treatment decisions by providing comprehensive organism identification and resistance profiling within hours. This innovation addresses critical healthcare challenges, particularly in the treatment of life-threatening infections like sepsis, where timely intervention is essential. DZD's services are primarily targeted at hospitals and healthcare facilities where the threat of antibiotic resistance is significant, with applications spanning both domestic and international markets including the United States and select regions in Europe. The company’s epiXact® service further aids hospitals in controlling healthcare-associated infections (HAIs) by delivering insights on pathogen relatedness to infection control professionals in under two days.Day Zero Diagnostics generates revenue through direct partnerships with healthcare institutions and healthcare providers, leveraging their advanced diagnostic solutions as part of clinical workflows. These collaborations typically involve service agreements where hospitals and laboratories subscribe to DZD’s rapid testing technology, resulting in a seamless integration into their infectious disease management protocols. Transactions are structured as B2B agreements, focusing on service usage fees that are contingent on the volume of tests conducted, thereby aligning DZD’s offerings with the needs of its client base. The company’s revenue model is supported by their proprietary products, including the rapid antimicrobial susceptibility testing and the epiXact® service, which are critical in addressing the increasing urgency of antibiotic resistance in clinical settings. The pricing structure for these services is designed to reflect the value of rapid diagnostics in improving patient outcomes and optimizing antibiotic usage.In September 2023, Day Zero Diagnostics, Inc. raised USD 16.00 mn in venture funding from unspecified investors. The company will use the funding to accelerate its development of an improved Blood2Bac™ sample prep protocol, aiming to enhance its diagnostic capabilities. Furthermore, DZD plans to expand into additional international markets, specifically targeting regions in Europe and Asia, by the end of 2024.

## Funding rounds

- Series A, Feb 9, 2022, $21M — BD Ventures, Golden Seeds, Triventures, Sands Capital Alternatives, Panacea Venture, Hongkou Capital
- Series A, Jan 23, 2019, $8.6M — Golden Seeds, Triventures, Sands Capital Alternatives
- Seed, Aug 3, 2017, $3M — Golden Seeds, Sands Capital Alternatives

## Investors

- Golden Seeds (https://capitalatlas.ai/funds/golden-seeds) — Seed, Series A
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Seed, Series A
- Triventures (https://capitalatlas.ai/funds/triventures) — Series A
- BD Ventures (https://capitalatlas.ai/funds/bd-ventures) — Series A
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Series A
- Hongkou Capital — Series A